Neos Therapeutics (NASDAQ:NEOS) Cut to “Hold” at ValuEngine

Neos Therapeutics (NASDAQ:NEOS) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, ValuEngine reports.

NEOS has been the topic of several other research reports. BMO Capital Markets dropped their price objective on Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating on the stock in a research note on Monday, August 12th. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 18th.

Shares of NASDAQ:NEOS opened at $1.58 on Tuesday. Neos Therapeutics has a 52-week low of $1.13 and a 52-week high of $3.62. The stock has a market cap of $82.55 million, a P/E ratio of -0.99 and a beta of 0.98. The business’s 50 day moving average is $1.52 and its 200 day moving average is $1.54. The company has a quick ratio of 0.91, a current ratio of 1.11 and a debt-to-equity ratio of 41.70.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.06. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 35.77%. The company had revenue of $17.54 million for the quarter. On average, sell-side analysts anticipate that Neos Therapeutics will post -0.31 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Weiss Asset Management LP bought a new stake in Neos Therapeutics during the 2nd quarter valued at $36,000. Acadian Asset Management LLC bought a new stake in Neos Therapeutics during the 2nd quarter valued at $40,000. D. E. Shaw & Co. Inc. bought a new stake in Neos Therapeutics during the 2nd quarter valued at $57,000. Algert Global LLC bought a new stake in Neos Therapeutics during the 2nd quarter valued at $100,000. Finally, Jane Street Group LLC boosted its position in Neos Therapeutics by 332.1% during the 2nd quarter. Jane Street Group LLC now owns 165,503 shares of the company’s stock valued at $213,000 after acquiring an additional 127,202 shares in the last quarter. 41.32% of the stock is currently owned by institutional investors and hedge funds.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: FinTech

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.